Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells.
about
Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancerMetabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol.Effects of lovastatin on breast cancer cells: a proteo-metabonomic study.Statin use and cancer risk: a comprehensive reviewHigh-density lipoprotein induces proliferation and migration of human prostate androgen-independent cancer cells by an ABCA1-dependent mechanismFluvastatin mediated breast cancer cell death: a proteomic approach to identify differentially regulated proteins in MDA-MB-231 cells.Statin use and the risk of recurrence after radical prostatectomy in a cohort of men with inherited and/or early-onset forms of prostate cancer.Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifenStatins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteinsMetabolic alterations and targeted therapies in prostate cancer.Statins inhibit the proliferation and induce cell death of human papilloma virus positive and negative cervical cancer cells.Statin use and prostate cancer risk in a large population-based setting.Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer.The prince and the pauper. A tale of anticancer targeted agents.Multiorgan-protective actions of blockers of the renin-angiotensin system, statins and erythropoietin: common pleiotropic effects in reno-, cardio- and neuroprotection.Atorvastatin activates heme oxygenase-1 at the stress response elements.Effects of statins on the prognosis of local and locally advanced renal cell carcinoma following nephrectomyDyslipidemia, statins and prostate cancer.The strategies to control prostate cancer by chemoprevention approaches.Minireview: SLCO and ABC transporters: a role for steroid transport in prostate cancer progression.The effect of statins on cancer cells--review.Synergistic Effects of Simvastatin and Irinotecan against Colon Cancer Cells with or without Irinotecan Resistance.Lovastatin enhances adenovirus-mediated TRAIL induced apoptosis by depleting cholesterol of lipid rafts and affecting CAR and death receptor expression of prostate cancer cells.Suppressive effects of simvastatin on the human acute promyelocytic leukemia NB4 cell line through the regulation of the nuclear factor-κB signaling pathway.Effect of statins type on incident prostate cancer risk: a meta-analysis and systematic review.Autocrine amplification loop in statin-induced apoptosis of human melanoma cells.Human caspase 7 is positively controlled by SREBP-1 and SREBP-2.Impact of treatment with statins on prostate-specific antigen and prostate volume in patients with benign prostatic hyperplasia.Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies.The association between statins and cancer incidence in a veterans population.The dichotomous role of H2S in cancer cell biology? Déjà vu all over again.Simvastatin in combination with meclofenamic acid inhibits the proliferation and migration of human prostate cancer PC-3 cells via an AKR1C3 mechanism.Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer.Topical mevastatin promotes wound healing by inhibiting the transcription factor c-Myc via the glucocorticoid receptor and the long non-coding RNA Gas5.Cholesterol synthesis pathway genes in prostate cancer are transcriptionally downregulated when tissue confounding is minimized.
P2860
Q33548538-9EDDCFBD-F495-4C91-86E8-0F7E08B6AFFFQ33769607-E349C3AB-957D-4DAD-B60E-97FBB0AF5A67Q33889477-920421BF-70A8-491C-BFF3-97EBD0D15808Q34021312-CC3C9ACF-3046-4836-BABC-3D272EA362DDQ34137900-18903967-311E-41A6-9519-DB2B01C538DCQ34277789-7A3E7BA8-57B8-4A82-9E9F-FCFD223A856BQ34502662-C986A0A5-9479-40C8-B7BF-4A4E18BA82D9Q35029556-CEF9352D-9342-4869-8223-AF938504EFF8Q35264079-97464B18-6083-4AE3-B7EB-A45E3D71E856Q35401667-190A9F50-5F18-408C-AA45-D964B84A7263Q36735614-CF1F9F2C-84AC-43EE-8F16-57BB25B87A9BQ36953616-04D2348C-44D5-4EB7-8DDC-0267070258C6Q37038650-F700D00F-72DF-455C-B89E-633665653BA5Q37042365-11559782-CED5-4326-B2BD-35D417264024Q37247753-BE8BE92C-EE8E-4ADA-B6E9-EEA6B405AEB2Q37295799-D42269C7-3A35-46FD-8D87-4F9B98294BD3Q37641097-237DDEA9-0BB9-4311-9E28-E692388ADEAEQ38030598-AF5D5C27-E3A5-4DD9-B765-36832FA0E306Q38175776-B21CC234-E8C7-4C48-A066-037BC87AAF0AQ38242231-4B3BA0A8-ACBF-4AD4-A7A7-13F492D391ADQ38499265-2B5C5A00-8ECE-4FA1-A475-3F2FE4FA9623Q38540360-292B90ED-3B5A-45E3-BBDE-3C1DE3338317Q38918249-AD145056-DC2F-4E4C-B3E5-36E0065351A8Q38976416-7DA923FC-6F9C-40EF-A5BA-E1BD42A8CB46Q39031198-5D8990C9-AF85-4D1A-A51A-B41C1803249FQ39831618-CDF83AA2-B742-45C4-A65B-EE5DA5F7AC36Q39867942-43EB7722-5D7F-4E12-9AAA-7AE1E1A7C4D5Q43708471-8AF8D296-713A-4E8D-B9E8-949BE5E55FCEQ44560037-4E02F57F-9528-4BB4-8B15-833A27916306Q45332064-63AB7EB4-352A-4785-B553-C6FB2362FB8CQ49346285-7B604B92-ECCF-4988-AC0E-F31DADF9517CQ50053255-622A1627-FC90-4B11-84AA-4D512C1FF59FQ50068799-11A422CD-D8F3-436A-BC98-440DA21299F1Q52776767-EFE3577B-5B55-4D9F-A11D-5EAF2D01ABF2Q54960557-BCEE5294-0059-4DC1-A3CA-945930349906
P2860
Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells.
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Differential efficacy of 3-hyd ...... ycle of prostate cancer cells.
@ast
Differential efficacy of 3-hyd ...... ycle of prostate cancer cells.
@en
type
label
Differential efficacy of 3-hyd ...... ycle of prostate cancer cells.
@ast
Differential efficacy of 3-hyd ...... ycle of prostate cancer cells.
@en
prefLabel
Differential efficacy of 3-hyd ...... ycle of prostate cancer cells.
@ast
Differential efficacy of 3-hyd ...... ycle of prostate cancer cells.
@en
P1476
Differential efficacy of 3-hyd ...... ycle of prostate cancer cells.
@en
P2093
Umasundari Sivaprasad
P304
P356
10.1158/1535-7163.MCT-06-0175
P577
2006-09-01T00:00:00Z